Abstract
May 2007, sorafenib (Nexavar®) was approved for “unresectable hepatocellular carcinoma (HCC)”, and was the first molecular targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent, whose survival benefit has been demonstrated in two global phase III randomized controlled trials, and has now been approved worldwide. Phase III clinical trials of other molecular targeted agents comparing them with sorafenib as first-line treatment agents are now ongoing. Phase III clinical trials of several targeted agents comparing them with placebo as second-line treatment agents for patients who failed or was intolerable to sorafenib are also ongoing. In addition, combination of sorafenib with standard treatment such as resection, ablation, transarterial chemoembolization, and hepatic arterial infusion chemotherapy are ongoing.This review outlines the clinical utility of sorafenib in the treatment algorithm of HCC. Furthermore, it also reviews the current status of clinical trials of new agents or combination therapy with sorafenib and standard treatment. Finally, further prospect of the paradigm shift of the HCC treatment is also discussed.
Keywords: Brivanib, complete remission, everolimus, hepatocellular carcinoma, molecular targeted agent, sorafenib, acidic fibroblast growth factor, alpha-fetoprotein, alanine transaminase, aspartate transaminase, basic fibroblast growth factor, best supportive care, complete response, des-gamma-carboxyprothrombin, dose-limiting toxicities, epidermal growth factor, epidermal growth factor receptor, fibroblast growth factor
Current Cancer Drug Targets
Title:Targeted Therapy for Liver Cancer: Updated Review in 2012
Volume: 12 Issue: 9
Author(s): Masatoshi Kudo
Affiliation:
Keywords: Brivanib, complete remission, everolimus, hepatocellular carcinoma, molecular targeted agent, sorafenib, acidic fibroblast growth factor, alpha-fetoprotein, alanine transaminase, aspartate transaminase, basic fibroblast growth factor, best supportive care, complete response, des-gamma-carboxyprothrombin, dose-limiting toxicities, epidermal growth factor, epidermal growth factor receptor, fibroblast growth factor
Abstract: May 2007, sorafenib (Nexavar®) was approved for “unresectable hepatocellular carcinoma (HCC)”, and was the first molecular targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent, whose survival benefit has been demonstrated in two global phase III randomized controlled trials, and has now been approved worldwide. Phase III clinical trials of other molecular targeted agents comparing them with sorafenib as first-line treatment agents are now ongoing. Phase III clinical trials of several targeted agents comparing them with placebo as second-line treatment agents for patients who failed or was intolerable to sorafenib are also ongoing. In addition, combination of sorafenib with standard treatment such as resection, ablation, transarterial chemoembolization, and hepatic arterial infusion chemotherapy are ongoing.This review outlines the clinical utility of sorafenib in the treatment algorithm of HCC. Furthermore, it also reviews the current status of clinical trials of new agents or combination therapy with sorafenib and standard treatment. Finally, further prospect of the paradigm shift of the HCC treatment is also discussed.
Export Options
About this article
Cite this article as:
Kudo Masatoshi, Targeted Therapy for Liver Cancer: Updated Review in 2012, Current Cancer Drug Targets 2012; 12 (9) . https://dx.doi.org/10.2174/15680096112091062
DOI https://dx.doi.org/10.2174/15680096112091062 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HPV Vaccination in Adolescents: From Clinical Data to Implementation and Practice
Current Cancer Therapy Reviews Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Old Wine in a New Bottle: The Warburg Effect and Anticancer Mechanisms of Resveratrol
Current Pharmaceutical Design Pathophysiological Functions of the lncRNA TUG1
Current Pharmaceutical Design Anti-Biofilm Strategies and the Need for Innovations in Wound Care
Recent Patents on Anti-Infective Drug Discovery Biochemical and Structural Insights into the Eukaryotic Translation Initiation Factor eIF4E
Current Protein & Peptide Science Evaluating the Effect of Integra Seeded with Adipose Tissue-Derived Stem Cells or Fibroblasts in Wound Healing
Current Drug Delivery Helicobacter Pylori, Zinc and Iron in Oxidative Stress-Induced Injury of Gastric Mucosa
Mini-Reviews in Medicinal Chemistry Bicycloheptylamine-Doxorubicin Conjugate: Synthesis and Anticancer Activities in σ2 Receptor-Expressing Cell Lines
Medicinal Chemistry Editorial [Hot Topic: Calcium Metabolism and Treatment of Hypercalcemia]
Medicinal Chemistry 5-Hydroxymethylfurfural (HMF) in Organic Synthesis: A Review of its Recent Applications Towards Fine Chemicals
Current Organic Synthesis Prostatic Tumor Stroma: A Key Player in Cancer Progression
Current Cancer Drug Targets The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Functional Foods Market and Consumer Perspective
Current Nutrition & Food Science 3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors
Medicinal Chemistry Meet Our Editorial Board Member:
Current Drug Targets Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Editorial (Hot Topic: Human Therapeutics: A Nanotechnology Approach)
Current Drug Metabolism Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition
Anti-Cancer Agents in Medicinal Chemistry Editorial [Special Board Members Issue}
Anti-Cancer Agents in Medicinal Chemistry